Valuation: Arcus Biosciences, Inc.

Market Cap 386.33Cr 331.08Cr 309.73Cr 283.17Cr 534.37Cr 37TCr 540.05Cr 3.67TCr 1.43TCr 19TCr 1.45TCr 1.42TCr 61TCr P/E 2026 *
-8.48x
P/E 2027 * -8.42x
Enterprise Value 342.26Cr 293.32Cr 274.4Cr 250.87Cr 473.42Cr 33TCr 478.45Cr 3.25TCr 1.26TCr 16TCr 1.29TCr 1.26TCr 54TCr EV / Sales 2026 *
43.5x
EV / Sales 2027 * 72.2x
Free-Float
71.2%
Yield 2026 *
-
Yield 2027 * -
1 day+1.24%
1 week+3.67%
Current month+8.71%
1 month+7.83%
3 months+27.00%
6 months+51.78%
Current year+28.60%
1 week 28.94
Extreme 28.94
31.28
1 month 26.19
Extreme 26.19
31.28
Current year 18.52
Extreme 18.515
31.74
1 year 10.07
Extreme 10.07
31.74
3 years 6.5
Extreme 6.5
31.74
5 years 6.5
Extreme 6.5
49.1
10 years 6.3
Extreme 6.3
49.1
Manager TitleAgeSince
President 68 01/05/2015
Chief Executive Officer 67 01/05/2015
Director of Finance/CFO 53 01/08/2020
Director TitleAgeSince
Chairman 67 01/12/2017
Director/Board Member 65 18/09/2017
Director/Board Member 72 01/05/2015
Date Insider Type Main position Quantity % Market Cap.
10/07/26 Sell

Founder

-20,067 0.0160%
11/06/26 Free

Director

22,600 0.0180%
23/01/26 Free

Chief Financial Officer

1,57,000 0.1269%
Change 5-day change 1-year change 3-year change Capi.($)
+1.30%+3.67%+201.92%+33.70% 386.33Cr
-0.74%+3.78%+2.62%+23.10% 5.16TCr
+0.19%-1.25%+486.94%+557.95% 4.49TCr
-0.32%+7.44%+37.85%+20.26% 4.28TCr
-0.59%+2.57%+20.48%+86.96% 4.26TCr
+0.88%-3.48%+17.20%+57.20% 3.18TCr
-0.92%+2.90%+31.63%+143.04% 1.73TCr
-0.57%+1.64% - - 1.66TCr
+0.58%+4.66%+9.77%+30.87% 1.48TCr
-0.52%+2.54%+79.10%+47.98% 1.41TCr
Average -0.13%+4.64%+98.61%+111.23% 2.8TCr
Weighted average by Cap. -0.31%+5.10%+104.74%+137.92%

Financials

2026 *2027 *
Net sales 7.86Cr 6.74Cr 6.3Cr 5.76Cr 11Cr 752.69Cr 11Cr 75Cr 29Cr 377.96Cr 30Cr 29Cr 1.25TCr 5.21Cr 4.46Cr 4.18Cr 3.82Cr 7.2Cr 498.66Cr 7.28Cr 49Cr 19Cr 250.4Cr 20Cr 19Cr 828.48Cr
Net income -45Cr -39Cr -36Cr -33Cr -62Cr -4.32TCr -63Cr -427.85Cr -166.37Cr -2.17TCr -169.33Cr -165.67Cr -7.17TCr -45Cr -39Cr -36Cr -33Cr -62Cr -4.32TCr -63Cr -428.12Cr -166.47Cr -2.17TCr -169.44Cr -165.77Cr -7.18TCr
Net Debt -44Cr -38Cr -35Cr -32Cr -61Cr -4.22TCr -62Cr -418.04Cr -162.55Cr -2.12TCr -165.45Cr -161.87Cr -7.01TCr -10Cr -8.76Cr -8.19Cr -7.49Cr -14Cr -978.21Cr -14Cr -97Cr -38Cr -491.2Cr -38Cr -38Cr -1.63TCr
Logo Arcus Biosciences, Inc.
Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. The Company has a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting lung and gastrointestinal cancers. The Company has approximately seven clinical programs that are focused on targets, including TIGIT, PD-1, adenosine A2a and A2b receptors, CD73, CD39, HIF-2a, and AXL. The Company is engaged in co-developing four investigational products, including zimberelimab (Arcuss anti-PD-1 molecule), domvanalimab (Arcuss anti-TIGIT antibody), etrumadenant (Arcuss adenosine receptor antagonist) and quemliclustat (Arcuss CD73 inhibitor). It is engaged in pursuing a Phase II and Phase III development program for domvanalimab in combination with its anti-PD-1 antibody, zimberelimab, in multiple settings, including lung and gastrointestinal cancer.
Employees
601
Date Price Change Volume
24/26/24 $30.59 +0.81% 5,26,352
21/26/21 $30.34 +2.78% 10,55,172
20/26/20 $29.52 -2.73% 15,46,249
19/26/19 $30.35 +2.85% 18,16,243
18/26/18 $29.51 -0.17% 8,96,392
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
30.34USD
Average target price
38.33USD
Spread / Average Target
+26.35%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. RCUS Stock